Myriad Genetics Presents Tumor Origin Technology at AACR
Determining Tumor Origin May Be Useful in Cancer TreatmentDecisions SALT LAKE CITY, UT, April 18, 2007--Myriad Genetics, Inc.(NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com ) announced today thatit presented studies for a new technology that might be used todetermine the original location of a metastatic tumor, on Monday,April 16, 2007 at the ann...Myriad Genetics Presents Azixa's Mode of Action at AACR
Azixa Shows Dual Activity as Vascular Disrupting Agent andTubulin Inhibitor SALT LAKE CITY, UT, April 17, 2007—Myriad Genetics, Inc.(NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com ) announced today thatit presented studies that characterize the mode of action of itsinvestigational new drug, Azixa™, as a vascular disruptingagent, at th...